Wegovy tablets (oral semaglutide) results: what the evidence shows

The weight-management licence for Wegovy tablets (oral semaglutide) is based mainly on the OASIS programme of randomised controlled trials, which compared semaglutide (oral) with placebo in people also following diet and activity advice. Our in-depth guides summarise each trial and link to the published papers.

Trial averages do not predict what will happen to any individual. Results vary with dose, how long treatment continues, other health conditions and changes to diet and activity. Some people lose much less weight than average.